693 related articles for article (PubMed ID: 25864647)
21. Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.
Jiang QW; Cheng KJ; Mei XL; Qiu JG; Zhang WJ; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Zhang X; Lv M; Chen MW; Wei X; Shi Z
Oncotarget; 2015 Oct; 6(32):32790-804. PubMed ID: 26447544
[TBL] [Abstract][Full Text] [Related]
22. Sodium arsenite inhibited genomic estrogen signaling but induced pERα (Ser118) via MAPK pathway in breast cancer cells.
Nakareangrit W; Thiantanawat A; Visitnonthachai D; Watcharasit P; Satayavivad J
Environ Toxicol; 2016 Sep; 31(9):1133-46. PubMed ID: 25728338
[TBL] [Abstract][Full Text] [Related]
23. Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolide-induced apoptosis.
Tan BJ; Chiu GN
Int J Oncol; 2013 May; 42(5):1605-12. PubMed ID: 23467622
[TBL] [Abstract][Full Text] [Related]
24. Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells.
Farooqui M; Geng ZH; Stephenson EJ; Zaveri N; Yee D; Gupta K
Mol Cancer Ther; 2006 Mar; 5(3):611-20. PubMed ID: 16546975
[TBL] [Abstract][Full Text] [Related]
25. Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling.
Tian J; Wang Y; Zhang X; Ren Q; Li R; Huang Y; Lu H; Chen J
J Exp Clin Cancer Res; 2017 Nov; 36(1):153. PubMed ID: 29096683
[TBL] [Abstract][Full Text] [Related]
26. Furanodienone inhibits cell proliferation and survival by suppressing ERα signaling in human breast cancer MCF-7 cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
J Cell Biochem; 2011 Jan; 112(1):217-24. PubMed ID: 21069738
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of estrogen receptor-alpha and rearranged during transfection tyrosine kinase is associated with withaferin a-induced apoptosis in MCF-7 breast cancer cells.
Zhang X; Mukerji R; Samadi AK; Cohen MS
BMC Complement Altern Med; 2011 Oct; 11():84. PubMed ID: 21978374
[TBL] [Abstract][Full Text] [Related]
28. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
29. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
Jin Y; Chen Q; Shi X; Lu Z; Cheng C; Lai Y; Zheng Q; Pan J
Cancer Sci; 2009 Jul; 100(7):1335-43. PubMed ID: 19383029
[TBL] [Abstract][Full Text] [Related]
30. Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells.
Tan BJ; Tan BH; Chiu GN
Oncol Rep; 2011 Nov; 26(5):1315-21. PubMed ID: 21805042
[TBL] [Abstract][Full Text] [Related]
31. Exosomes Mediated Transfer of Circ_UBE2D2 Enhances the Resistance of Breast Cancer to Tamoxifen by Binding to MiR-200a-3p.
Hu K; Liu X; Li Y; Li Q; Xu Y; Zeng W; Zhong G; Yu C
Med Sci Monit; 2020 Aug; 26():e922253. PubMed ID: 32756532
[TBL] [Abstract][Full Text] [Related]
32. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
[TBL] [Abstract][Full Text] [Related]
33. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
Liu J; Li Y
Biochem Biophys Res Commun; 2015 Nov; 467(2):242-7. PubMed ID: 26436206
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression.
Andruska ND; Zheng X; Yang X; Mao C; Cherian MM; Mahapatra L; Helferich WG; Shapiro DJ
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4737-42. PubMed ID: 25825714
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.
Yao Y; Brodie AM; Davidson NE; Kensler TW; Zhou Q
Breast Cancer Res Treat; 2010 Nov; 124(2):585-91. PubMed ID: 20623181
[TBL] [Abstract][Full Text] [Related]
36. A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.
Suh YA; Kim JH; Sung MA; Boo HJ; Yun HJ; Lee SH; Lee HJ; Min HY; Suh YG; Kim KW; Lee HY
Cancer Lett; 2013 May; 332(1):102-9. PubMed ID: 23348700
[TBL] [Abstract][Full Text] [Related]
37. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
38. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
39. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
40. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
